The GID Group, Inc. is the leading global provider of products and methods to process regenerative cells and adult stem cells from fat (adipose) and bone tissues.  Our technology separates and concentrates the regenerative fraction of cells from the tissues in real-time in the operating room or laboratory, enabling therapeutic application in a single surgical treatment.  GID uses a deep science-based approach to “cell-based therapies” based on use of regenerative cells, alone or in combination with various tissue scaffolds/matrices.

What cells exist in adipose tissue, and what do they do?

Adipose tissue is composed of adipocytes, extracellular matrix (ECM), vasculature, and a heterogeneous population of nucleated cells tightly adhered to the ECM, adipocytes, and vasculature, referred to as the ‘stromal vascular fraction’ (SVF). A diagrammatic representation of whole adipose tissue is shown above. (Adapted from Alderman,D, Alexander, R.W.: JOP (2011) Vol. 3)

The stromal and vascular cells (CD45-) are useful and functional for repair or regeneration of stromal or vascular tissues.  The stromal and vascular nucleated cells (SVF) can be further segmented by classes of cell types, function, and percentage of the SVF population.

Angiogenesis refers to the capacity to induce formation of blood supply (vasculature).  Reparative/regenerative refers to the ability to induce ECM remodeling and anti-fibrotic and anti-apoptotic properties.  Immunomodulatory refers to the anti-inflammatory and anti-microbial properties, and the ability to regulate the immune response.

Why must SVF cells be harvested and concentrated for therapeutic application?

Stromal and vascular cells are ‘anchored cells’ in the adipose tissue matrix and are tightly adhered to the extracellular matrix and the vascular walls. In order to obtain a therapeutic dose of the SVF cells the adipose tissue must be harvested (usually a very small lipoharvest procedure), then the SVF cells separated from the adipose tissue matrix, and then concentrated to form the therapeutic dose. Adipose tissue is the richest source of SVF cells per gram of tissue in the body, particularly with respect to the stromal and pericyte progenitor cells. However, adipose tissue is more than 99% adipocyte and ECM by volume, thus the concentration of the SVF cells in whole adipose is very dilute.

The GID technology reduces an entire GMP cell-processing facility to a single sterile disposable device. The processing steps are as follows: 1. Adipose tissue is harvested directly into the sterile device. 2. Adipose tissue is washed (in the same device) to remove the blood phase (leukocytes and erythrocytes), and oil phase from ruptured adipocytes 3. Adipose tissue is separated into components, including nucleated cells and ECM/vasculature. 4. Adipocytes and ECM are removed using filters and centrifugation. 5. Concentrated SVF cells are removed and resuspended. 6. The tissue processing is completed in less than 60 minutes.

1. Orthopedics

Cell-based solutions to joint and musculoskeletal tissue repair and reconstruction in orthopedics, including osteoarthritis, tendon and ligament repair, fracture healing, and disc repair.

2. Soft-tissue

Cell-based solutions for soft-tissue repair and reconstruction of dermal tissues (epidermal, dermal, and hypodermal layers) including treatment of chronic wounds, burns, scars, and radiation injury. Aesthetic applications include alopecia (hair loss) and small-volume facial filler.

3. Tissue

Cell-based solution to repair and regeneration of organ tissues, including application to erectile dysfunction and COPD.